QuidelOrtho

QDEL

Market cap $1.86B

SAN DIEGO , Nov. 24, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: Evercore ISI 8th Annual Healthcare Conference, Tuesday, December 2, 2025 Members of QuidelOrtho's management team are scheduled to participate in a fireside chat at 10:00 a.m. ET / 7:00 a.m.

SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 53 of its Science Bytes podcast, featuring Qian Ding, MD, PhD, Senior Medical Affairs Manager, QuidelOrtho, an expert in clinical and laboratory medicine with deep experience in healthcare information systems and data analytics. In the episode titled "Don't Wait for the Wake-Up Call," Dr. Ding explains why early detection of diabetes is a clinical and economic priority.

QDEL tops Q3 estimates as Labs and Immunohematology units drive growth, while margins strengthen despite respiratory revenue declines.

QuidelOrtho Corporation ( QDEL ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Juliet Cunningham - Vice President of Investor Relations Brian Blaser - President, CEO & Director Joseph Busky - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair & Company L.L.C., Research Division Lu Li - UBS Investment Bank, Research Division Jack Meehan - Nephron Research LLC Jack Melick - Jefferies LLC, Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Welcome to the QuidelOrtho Third Quarter 2025 Financial Results Conference Call and webcast.

―  Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ― ― Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ―  Third Quarter 2025 Results (all comparisons are to the prior year period)                                   Total revenue was $700 million, as reported Non-respiratory revenue was $588 million, an increase of 5% as reported and 4% in constant currency; excluding Donor Screening1, non-respiratory revenue grew 6% in constant currency Labs revenue grew 5% as reported and 4% in constant currency Respiratory revenue was $112 million as reported; the decline was primarily driven by a 63% decrease in COVID-19 revenue GAAP operating expenses2 decreased by 6%; non-GAAP operating expenses decreased by 7%, both driven by the Company's cost-savings initiatives GAAP net loss margin was (105%); GAAP operating margin was (101%), which included a $701 million non-cash goodwill impairment charge (see description below); adjusted EBITDA margin was 25%, a 180 basis point improvement compared to the prior year period GAAP diluted loss per share was $10.78; adjusted diluted earnings per share ("EPS") was $0.80 SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the third quarter ended September 28, 2025. "Our third quarter results reflect continued execution and meaningful progress against our strategic and financial priorities," said Brian J.

Clearance expands menu and enables high-sensitivity troponin I measurement to aid in the diagnosis of myocardial infarction SAN DIEGO , Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) clearance for the VITROS hs Troponin I Reagent Pack (the "VITROS hs Troponin I Assay"). The assay is intended for the quantitative measurement of cardiac troponin I (cTnI) in human plasma (heparin) to aid in the diagnosis of myocardial infarction (MI).

SAN DIEGO , Oct. 23, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released Episode 52 of its Science Bytes podcast, featuring George Wierschem, MBA, MT(ASCP), Senior Global Product Manager – Informatics. In the episode titled "The Power of Informatics in Clinical Decision-Making," Wierschem shares how informatics platforms are transforming laboratory operations by connecting instruments, data systems and clinical decisions.

SAN DIEGO , Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m.

FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine SAN DIEGO , Oct. 16, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, will highlight its ongoing commitment to transfusion medicine excellence at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting. The company's participation coincides with the recent FDA approval of its Micro Typing Systems (MTS) DAT Card and the continued expansion of its comprehensive direct antiglobulin testing and immunohematology portfolio.

QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.